FDA grants J&J accelerated approval for head and neck cancer treatmentThe FDA granted accelerated approval to Johnson & Johnson's treatment for patients with advanced head and neck cancer whose disease has worsened after prior therapy.Nov 5, 2026·2 sourcesFDA drug approvalCancer & OncologyAccelerated approval pathwaysTargeted cancer therapyDrug Policy, Pricing & ApprovalBiologic therapiesClinical trialsAdvanced drug delivery formulations00
